Company Overview

Amphastar Pharmaceuticals, Inc. is a U.S.-based specialty pharmaceutical company focused on the development, manufacturing, marketing, and sale of technically challenging generic and proprietary injectable, inhalation, and intranasal products. The company operates primarily within the generic pharmaceuticals, specialty pharmaceuticals, and active pharmaceutical ingredient (API) manufacturing industries. Its core revenue is driven by complex dosage-form generics, insulin products, and select proprietary drugs, with customers including hospitals, clinics, pharmacies, and wholesale distributors.

Founded in 1996, Amphastar evolved from a focus on injectable generics into a vertically integrated pharmaceutical manufacturer with in-house API capabilities. A key element of its strategic positioning is its ability to manufacture both finished dosage forms and critical APIs internally, which provides supply chain control and cost advantages. The company is also notable for owning and commercializing Primatene® Mist, the only FDA-approved over-the-counter epinephrine inhalation product for asthma.

Business Operations

Amphastar generates revenue primarily through the sale of injectable, inhalation, and intranasal pharmaceutical products, as well as insulin APIs and finished insulin products. While the company does not formally report separate operating segments, its business is commonly understood to consist of injectable products, inhalation and intranasal products, and insulin and API manufacturing. Sales are concentrated in the U.S. market, with additional revenue from international API and product sales.

The company controls a portfolio of FDA-approved manufacturing facilities and proprietary technologies supporting complex drug delivery systems. Amphastar operates through several subsidiaries, including International Medication Systems (IMS), Amphastar Nanjing Pharmaceuticals, and Amphastar Shanghai Pharmaceuticals, which support manufacturing, research, and API production. These subsidiaries enable vertical integration and support both domestic and international supply.

Strategic Position & Investments

Amphastar’s strategy emphasizes growth through complex generics, expansion of proprietary products, and continued investment in insulin and API manufacturing capabilities. The company has invested significantly in expanding insulin production capacity and developing differentiated products that face higher regulatory and technical barriers to entry. Its ownership of Primatene® Mist represents a notable proprietary asset within an otherwise generic-focused portfolio.

Strategic investments have included the acquisition of International Medication Systems, which expanded Amphastar’s injectable manufacturing capabilities, and continued capital investment in Chinese subsidiaries to secure API supply. The company is also involved in emerging drug delivery technologies related to inhalation and intranasal administration, which management has identified as long-term growth areas.

Geographic Footprint

Amphastar is headquartered in Rancho Cucamonga, California, and maintains significant operations across North America and Asia. Its primary commercial market is the United States, where the majority of finished pharmaceutical products are sold. Manufacturing and API production are supported by facilities in California and China, providing both domestic reliability and international cost efficiency.

Internationally, the company’s presence in China through Amphastar Nanjing Pharmaceuticals and Amphastar Shanghai Pharmaceuticals plays a critical role in API manufacturing and early-stage production. These operations support Amphastar’s global supply chain and provide strategic leverage in sourcing key pharmaceutical inputs.

Leadership & Governance

Amphastar is led by its founder, who continues to shape the company’s long-term strategy with an emphasis on vertical integration, regulatory expertise, and technically complex products. Leadership has consistently articulated a strategy centered on disciplined capital allocation, internal manufacturing control, and sustainable growth in high-barrier pharmaceutical niches.

Key executives include:

• Jack Zhang – Chairman of the Board and Chief Executive Officer
• Frank Wu – Chief Financial Officer
• Chongyi Zhang – President
• Lynn Lin – Senior Vice President, Regulatory Affairs

The leadership team combines scientific, regulatory, and financial expertise, reflecting Amphastar’s focus on compliance-driven markets and technically demanding product categories.